graph Evidence gap map comparisons
Immune checkpoint association
durvalumab plus tremelimumab
mHNSCC - L2 - PDL1 negative 2    
Comparator:  vs durvalumab alone;   vs tremelimumab; 
Risk of bias:  low;   some concerns;   high;  NA;